• Q-VD(OMe)-OPh in Apoptosis Workflow Design

  2026-09-23

  Use Q-VD(OMe)-OPh to test whether caspase-dependent apoptosis contributes to a treatment response—without mistaking reduced apoptosis for proof that every form of cell death has been blocked. This workflow connects the inhibitor to a colorectal cancer resistance study and offers practical controls, dose-finding guidance, and interpretation limits for apoptosis assays.

• OTUD7B, p62, and IRF3 in Antiviral Immunity

  2026-09-23

  The reference study identifies OTUD7B as a negative regulator of antiviral immunity that activates SQSTM1/p62 through deubiquitination and promotes selective autophagic degradation of IRF3. Its findings connect ubiquitin-chain editing, cargo-receptor oligomerization, and type I interferon control, providing a mechanistic framework for studying how antiviral signaling is terminated.

• Phosbind Biotin: Reading Stress-Driven Phosphorylation

  2026-09-22

  Phosbind Biotin offers sequence-independent support for protein phosphorylation analysis in plant stress research. This article explains how to interpret its membrane-based readout alongside the PtrbZIP12 drought-resistance model and how to distinguish screening evidence from mechanistic proof.

• Bay 11-7821 for NF-κB Assay Workflows

  2026-09-22

  Bay 11-7821, also known as BAY 11-7082, provides a practical pharmacological handle for separating IKK-dependent NF-κB transcription from broader macrophage inflammatory responses. This workflow shows how to combine reporter, viability, apoptosis, and HMGB1-release assays while avoiding solvent, precipitation, and pathway-interpretation errors.

• CRISPR/Cpf1 Enables DNA-Free Plant Genome Editing

  2026-09-21

  Kim and colleagues demonstrated that recombinant Cpf1–crRNA ribonucleoprotein complexes can introduce targeted mutations in soybean and wild tobacco protoplasts without delivering editing DNA. The study establishes a practical DNA-free plant genome-editing framework and shows distinctive deletion patterns, while also highlighting the importance of target design, delivery, and deep-sequencing validation.

• SW033291: From PGE2 Signals to Repair Assays

  2026-09-21

  SW033291 is a mechanistically defined 15-PGDH inhibitor for connecting prostaglandin E2 elevation with hematopoiesis and tissue repair. This article translates recent muscle-regeneration findings into a practical, endpoint-driven framework for biochemical, cellular, and functional assay design.

• Iptacopan: From C3bBb Biology to Translation

  2026-09-20

  Iptacopan (LNP023) illustrates how selective, reversible factor B inhibition can connect alternative-pathway mechanism, complement-mediated hemolysis assays, animal models, and translational strategy. This thought-leadership perspective interprets the PNH evidence while outlining how researchers can build more decision-ready complement activation studies.

• Valemetostat: From EZH2 Potency to Lymphoma Evidence

  2026-09-19

  Valemetostat (DS-3201) is examined here through an evidence-to-assay framework linking EZH2 biochemistry, chromatin pharmacology, and lymphoma response. Learn how to interpret potency, clinical findings, and research-use handling without confusing molecular inhibition with therapeutic efficacy.

• GVBE Editing of Maternal Alleles in Porcine Oocytes

  2026-09-18

  The reference study introduces germinal vesicle oocyte base editing (GVBE), a strategy for modifying maternal alleles during porcine oocyte maturation before fertilization. Using BE3 mRNA and Dmd-targeting guide RNAs, the authors generated embryos with relatively simple allele patterns and demonstrated a route toward non-mosaic or maternally defined point-mutant founders.

• Caspase-3 Fluorometric Assay Kit: RCC Workflow Guide

  2026-09-18

  Translate treatment-induced cell death into quantitative DEVD-dependent fluorescence with a practical workflow for renal cell carcinoma and broader apoptosis research. The assay pairs rapid microplate readout with inhibitor controls, ROS measurements, and autophagy-focused experiments to distinguish caspase activation from nonspecific loss of viability.

• T7 RNA Polymerase for Translational RNA Workflows

  2026-09-17

  T7 RNA Polymerase converts promoter-bearing DNA into defined RNA for assays spanning transcript stability, RNA structure, antisense design, and research-stage RNA vaccine production. This guide connects practical template engineering and troubleshooting with the DDX21–SIRT7–NAT10 findings reported in colorectal cancer research.

• Doxorubicin: Reproducible Cytotoxicity Workflows

  2026-09-17

  This scenario-based guide helps researchers standardize Doxorubicin exposure, viability readouts, resistance studies, and reagent selection. It explains how SKU A3966 can support interpretable cancer-cell assays through defined handling guidance, literature context, and practical controls.

• Deferasirox in Ferroptosis Research Workflows

  2026-09-16

  Deferasirox is an oral iron chelator that can function as both a translationally relevant iron-depletion tool and a mechanistic control in ferroptosis studies. This guide connects practical dosing, oxygen-aware assay design, and troubleshooting to the METTL16-SENP3-LTF axis in hepatocellular carcinoma.

• Bay 11-7821: Mapping Inflammation to NF-κB

  2026-09-16

  Bay 11-7821 (BAY 11-7082) is a useful perturbation tool for connecting TLR-driven inflammation with NF-κB activity, apoptosis, and cytokine output. This article translates recent Chlamydia psittaci findings into assay-design principles for inflammatory signaling pathway research.

• Q-VD-OPh in Rab14–Parkin Mitophagy Assays

  2026-09-15

  Q-VD-OPh helps researchers separate caspase-dependent cell death from Rab14–Parkin mitophagy, improving interpretation of mitochondrial quality-control experiments. Its cell and brain permeability also supports apoptosis research, neurodegeneration models, and post-cryopreservation viability studies.

8816 records 1/588 page Next 12345 下5页 Last page